The short answer
Gatto and colleagues reviewed the effects of GLP-1 agonists on musculoskeletal health and orthopaedic care in Current Reviews in Musculoskeletal Medicine in 2025. This is a specialty that encounters these compounds through joint disease, surgical planning and perioperative management rather than through metabolic care.
Key facts
- Review
- Gatto 2025 (PMID 40372699)
- Journal
- Curr Rev Musculoskelet Med, October 2025
- Scope
- Musculoskeletal health and orthopaedic care
- Relevance
- Joint load, bone, muscle, perioperative
- Perioperative issue
- Delayed gastric emptying and anaesthesia
- Weight-bearing joints
- Load reduction is mechanical
Why a musculoskeletal specialty has its own view
Orthopaedics encounters obesity constantly: as a driver of joint degeneration, as a factor in surgical risk, and as a determinant of implant outcomes. A drug class producing 15 to 25% weight reduction changes all three at once, which makes it a specialty concern independent of anything metabolic.
Why weight matters mechanically at the knee
The knee experiences forces several times body weight during ordinary walking, because muscle contraction across the joint adds to the load gravity imposes. Reducing body mass therefore reduces joint force by a multiple of the mass lost. That is a mechanical argument, and it does not depend on any effect of the drug beyond the weight change.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The perioperative question
Delayed gastric emptying means stomach contents may remain longer than fasting guidance assumes, which matters for anaesthesia because it affects aspiration risk. That is a scheduling and assessment problem for surgical teams rather than a pharmacological one, and it arises for any procedure requiring sedation.
The competing considerations for surgery
Weight reduction before joint replacement may improve outcomes and reduce complications. Against that sit the bone and lean mass changes accompanying rapid weight loss, and the perioperative gastric emptying issue. A specialty review is where those are weighed together rather than considered one at a time.
Why this is a different question from the metabolic one
Metabolic medicine asks whether the drug improves glycaemia, cardiovascular risk or organ outcomes. Orthopaedics asks whether a patient is a better surgical candidate afterwards, and whether the tissue being operated on has changed. Those are separate questions and neither literature answers the other's.
What this does not concern
Research material. These are licensed medicines encountered in clinical practice. Nothing supplied on this site is a GLP-1 receptor agonist, is relevant to surgical planning, or has any bearing on the care of any person.
Frequently asked questions
Why do orthopaedic specialists care about GLP-1 drugs?
Obesity drives joint degeneration, surgical risk and implant outcomes. A drug producing 15-25% weight reduction changes all three.
How much does weight loss reduce knee load?
By a multiple of the mass lost, because the knee experiences forces several times body weight during walking as muscle contraction adds to gravitational load.
What is the perioperative concern?
Delayed gastric emptying means stomach contents may persist beyond what fasting guidance assumes, which affects aspiration risk under anaesthesia.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedGatto A et al., The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Curr Rev Musculoskelet Med 2025 (PMID 40372699)pubmed.ncbi.nlm.nih.gov
- PubMedBliddal H et al., Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. NEJM 2024 (PMID 39476339)pubmed.ncbi.nlm.nih.gov
- PubMedAnastasilakis AD et al. Diabetes Obes Metab 2025 (PMID 40555693)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- How Many People Are Still Taking It a Year LaterTrials report what happens to people who stay on treatment. Real-world persistence with GLP-1 therapies is the variable that decides whether that matters.
- Why a Drug Works Less Well Than Its Trial SaidEfficacy is performance under trial conditions; effectiveness is what happens in practice. The gap is predictable, and it has identifiable causes.
- Why Weight Loss Can Restore OvulationObesity and insulin resistance disrupt ovulation, particularly in PCOS. Reversing them can restore fertility - which is a documented effect, not a rumour.
- Restored Fertility and Reduced Contraceptive AbsorptionOne effect makes conception more likely; another can reduce contraceptive protection. They act in the same population, and neither announces itself.
- When the Reason for Treatment Causes the OutcomePeople given a drug differ from those not given it - by the condition that prompted it. A 2026 Danish cohort shows the problem unusually clearly.